This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collins, J. A. Articles by Alexander, L. Search for Related Content PubMed PubMed Citation Articles by Collins, J. A. Articles by Alexander, L.

 Previous Article  |  Next Article 

Journal of Virology, January 2004, p. 603-611, Vol. 78, No. 2
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.2.603-611.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Competitive Fitness of Nevirapine-Resistant Human Immunodeficiency Virus Type 1 Mutants

Jennifer A. Collins, M. Gregory Thompson, Elijah Paintsil, Melisa Ricketts, Joanna Gedzior, and Louis Alexander^*

Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut

Received 26 June 2003/ Accepted 26 September 2003

Determining the fitness of drug-resistant human immunodeficiency virus type 1 (HIV-1) strains is necessary for the development of population-based studies of resistance patterns. For this purpose, we have developed a reproducible, systematic assay to determine the competitive fitness of HIV-1 drug-resistant mutants. To demonstrate the applicability of this assay, we tested the fitness of the five most common nevirapine-resistant mutants (103N, 106A, 181C, 188C, and 190A), with mutations in HIV-1 reverse transcriptase (RT), singly and in combination (for a total of 31 variants) in a defined HIV-1 background. For these experiments, the 27 RT variants that produced viable virus were cocultured with wild-type virus without nevirapine. The ratios of the viral species were determined over time by utilization of a quantitative real-time RT-PCR-based assay. These experiments revealed that all of the viable variants were less fit than the wild type and demonstrated that the order of relative fitness of the single mutants tested was as follows: 103N > 181C > 190A > 188C > 106A. This order correlated with the commonality of these mutants as a result of nevirapine monotherapy. These investigations also revealed that, on average, the double mutants were less fit than the single mutants and the triple mutants were less fit than the double mutants. However, the fitness of the single and double mutants was often not predictive of the fitness of the derivative triple mutants, suggesting the presence of complex interactions between the closely aligned residues that confer nevirapine resistance. This complexity was also evident from the observation that all three of the replication-competent quadruple mutants were fitter than most of the triple mutants, and in some cases, even the double mutants. Our data suggest that, in many cases, viral fitness is the determining factor in the evolution of nevirapine-resistant mutants in vivo, that interactions between the residues that confer nevirapine resistance are complex, and that these interactions substantially affect reverse transcriptase structure and/or function.

J.C. and M.G.T. contributed equally to this work.

This article has been cited by other articles:

• Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
• Lalonde, M. S., Troyer, R. M., Syed, A. R., Bulime, S., Demers, K., Bajunirwe, F., Arts, E. J. (2007). Sensitive Oligonucleotide Ligation Assay for Low-Level Detection of Nevirapine Resistance Mutations in Human Immunodeficiency Virus Type 1 Quasispecies. J. Clin. Microbiol. 45: 2604-2615 [Abstract] [Full Text]  
• Held, D. M., Kissel, J. D., Thacker, S. J., Michalowski, D., Saran, D., Ji, J., Hardy, R. W., Rossi, J. J., Burke, D. H. (2007). Cross-Clade Inhibition of Recombinant Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus SIVcpz Reverse Transcriptases by RNA Pseudoknot Aptamers. J. Virol. 81: 5375-5384 [Abstract] [Full Text]  
• Cong, M.-e., Heneine, W., Garcia-Lerma, J. G. (2007). The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions. J. Virol. 81: 3037-3041 [Abstract] [Full Text]  
• Dykes, C., Wang, J., Jin, X., Planelles, V., An, D. S., Tallo, A., Huang, Y., Wu, H., Demeter, L. M. (2006). Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.. J. Clin. Microbiol. 44: 1930-1943 [Abstract] [Full Text]  
• Choi, J., Walker, J., Boichuk, S., Kirkiles-Smith, N., Torpey, N., Pober, J. S., Alexander, L. (2005). Human Endothelial Cells Enhance Human Immunodeficiency Virus Type 1 Replication in CD4+ T Cells in a Nef-Dependent Manner In Vitro and In Vivo. J. Virol. 79: 264-276 [Abstract] [Full Text]  
• Lee, D. J., Robinson, W. E. Jr. (2004). Human Immunodeficiency Virus Type 1 (HIV-1) Integrase: Resistance to Diketo Acid Integrase Inhibitors Impairs HIV-1 Replication and Integration and Confers Cross-Resistance to L-Chicoric Acid. J. Virol. 78: 5835-5847 [Abstract] [Full Text]